-2.78%
13.82%
-9.68%
-24.53%
-37.78%
-92.75%
-93.89%
AI Spotlight on MEIP
Company Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer.The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies.It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome.
MEI Pharma, Inc.has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc.The company was formerly known as Marshall Edwards, Inc.
and changed its name to MEI Pharma, Inc.in July 2012.MEI Pharma, Inc.
was incorporated in 2000 and is headquartered in San Diego, California.
Market Data
| Last Price | 2.8 |
| Change Percentage | -2.78% |
| Open | 2.83 |
| Previous Close | 2.88 |
| Market Cap ( Millions) | 19 |
| Volume | 7404 |
| Year High | 4.97 |
| Year Low | 2.3 |
| M A 50 | 2.71 |
| M A 200 | 2.96 |
Financial Ratios
| FCF Yield | -232.84% |
| Dividend Yield | 0.00% |
| ROE | -110.69% |
| Debt / Equity | 0.00% |
| Net Debt / EBIDTA | 18.41% |
| Price To Book | 0.75 |
| Price Earnings Ratio | -0.4 |
| Price To FCF | -0.43 |
| Price To sales | 0 |
| EV / EBITDA | -0.31 |
News
- Sep -19 - MEI Pharma Reports Fiscal Year End 2024 Cash Position
- Jul -22 - MEI Pharma to Consider Strategic Alternatives
- Jul -01 - 7 Undervalued Biotech Stocks to Buy for Big-Time Returns
- May -20 - National Bank of Canada FI Takes $36,000 Position in MEI Pharma, Inc. (NASDAQ:MEIP)
- May -14 - Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
- Feb -14 - MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
- Jan -16 - MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
- Nov -06 - MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock
- Oct -17 - MEI Pharma Recommends Stockholders Not to Consent
- Oct -02 - MEI Pharma Adopts Limited-Duration Stockholder Rights Plan
- Sep -29 - All You Need to Know About MEI Pharma, Inc. (MEIP) Rating Upgrade to Strong Buy
- Sep -28 - MEI Pharma Issues Statement Regarding Anson and Cable Car's Opportunistic Actions
- Sep -26 - MEI Pharma, Inc. (MEIP) Q4 2023 Earnings Call Transcript
- Sep -26 - MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights
- Sep -21 - MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023
- Sep -18 - MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car
- Aug -16 - MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer
- Jun -15 - MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
- May -11 - MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates
- Feb -10 - MEI Pharma, Inc. (MEIP) Q2 Earnings and Revenues Top Estimates
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Pharmaceutical Compounds
Expected Growth : 9.27 %
What the company do ?
MEI Pharma, Inc.'s pharmaceutical compounds are small molecule oncology drug candidates, including ME-401, a PI3K delta inhibitor, and ME-344, a mitochondrial inhibitor.
Why we expect these perspectives ?
MEI Pharma's 9.27% growth in Pharmaceutical Compounds is driven by increasing demand for cancer treatments, strategic partnerships, and a strong pipeline of novel oncology candidates. Additionally, the company's focus on precision medicine and targeted therapies has led to increased adoption and revenue growth.
Mei Pharma, Inc. Products
| Product Range | What is it ? |
|---|---|
| Pracinostat | A oral inhibitor of the enzyme histone deacetylase (HDAC) for the treatment of advanced hematologic malignancies |
| ME-344 | A mitochondrial inhibitor of complex I for the treatment of solid tumors |
| ME-401 | A PI3K delta inhibitor for the treatment of B-cell malignancies |
| Zandelisib | A PI3K delta inhibitor for the treatment of B-cell malignancies |
MEI Pharma, Inc.'s Porter Forces
Threat Of Substitutes
MEI Pharma, Inc. operates in a niche market with limited substitutes, reducing the threat of substitutes.
Bargaining Power Of Customers
MEI Pharma, Inc. has a diverse customer base, reducing the bargaining power of individual customers.
Bargaining Power Of Suppliers
MEI Pharma, Inc. relies on a few key suppliers, giving them some bargaining power, but the company's size and reputation mitigate this threat.
Threat Of New Entrants
The pharmaceutical industry is highly competitive, and new entrants can easily disrupt the market, posing a significant threat to MEI Pharma, Inc.
Intensity Of Rivalry
The pharmaceutical industry is highly competitive, with many established players, leading to intense rivalry and competition for market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 34.08% |
| Debt Cost | 3.95% |
| Equity Weight | 65.92% |
| Equity Cost | 7.43% |
| WACC | 6.24% |
| Leverage | 51.69% |
MEI Pharma, Inc. : Quality Control
MEI Pharma, Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| INVA | Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol … |
| CPRX | Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, … |
| HRTX | Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic … |
| ARMP | Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's … |
| SPRO | Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Innoviva
A-Score
1-Year Total Return ->
🥈
Catalyst Pharmaceuticals
A-Score
1-Year Total Return ->
🥉
MEI Pharma
A-Score
1-Year Total Return ->
4
Spero Therapeutics
A-Score
1-Year Total Return ->
5
Heron Therapeutics
A-Score
1-Year Total Return ->
6
